For people outside the science bubble: over the last 3 years, NIH researchers like me were informally encouraged to avoid working with mRNA technology in grant proposals. Pharmaceutical companies rely heavily on discoveries made with public funding first. This is the result:
Danielle Beckman
Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon. www.wired.com/story/a-new-...
Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon.
